Phosphoric Acid — predicted protein targets

Known targets — ChEMBL curated mechanism

ADRA1A ADRA1B ADRA1D ADRB1 ADRB2 ADRB3 CYP11B1 DPP4 FGFR1 FGFR2 FGFR3 FGFR4 HRH1 JAK1 JAK2 JAK3 KCNA1 KCNA10 KCNA2 KCNA3 KCNA4 KCNA5 KCNA6 KCNA7 KCNB1 KCNB2 KCNC1 KCNC2 KCNC3 KCNC4 KCND1 KCND2 KCND3 KCNF1 KCNG1 KCNG2 KCNG3 KCNG4 KCNH1 KCNH2 KCNH3 KCNH4 KCNH5 KCNH6 KCNH7 KCNH8 KCNQ1 KCNQ2 KCNQ3 KCNQ4 KCNQ5 KCNS1 KCNS2 KCNS3 KCNV1 KCNV2 KDR KIT NA OPRD1 OPRK1 OPRM1 P PDGFRB PIK3CD SCN10A SCN11A SCN1A SCN2A SCN3A SCN4A SCN5A SCN7A SCN8A SCN9A SMO TYK2 pol rplA rplB rplC rplD rplE rplF rplJ rplK rplL rplM rplN rplO rplP rplQ rplR rplS rplT rplU rplV rplW rplX rplY rpmA rpmB rpmC rpmD rpmE rpmF rpmG rpmH rpmI rpmJ rpsA rpsB rpsC rpsD rpsE rpsF rpsG rpsH rpsI rpsJ rpsK rpsL rpsM rpsN rpsO rpsP rpsQ rpsR rpsS rpsT rpsU ykgM ykgO

The experimentally established mechanism targets of Phosphoric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

	gene	UniProt	supporting neighbours	confidence
▸	ESR1	P03372	3/20	0.50

▸	ESR2	Q92731	3/20	0.50

▸	NQO2	P16083	1/20	0.46

▸	ALDH1A1	P00352	2/20	0.41

▸	MAPT	P10636	2/20	0.41

▸	KMT2A	Q03164	1/20	0.41

▸	HPGD	P15428	2/20	0.40

▸	CYP3A4	P08684	2/20	0.40

▸	CISD1	Q9NZ45	1/20	0.40

▸	KDM4E	B2RXH2	1/20	0.40

▸	SLC16A3	O15427	1/20	0.40

▸	SLC16A1	P53985	1/20	0.40

▸	GPR35	Q9HC97	1/20	0.40

▸	CA1	P00915	2/20	0.39

▸	CA2	P00918	2/20	0.39

▸	CA12	O43570	1/20	0.39

▸	CA3	P07451	1/20	0.39

▸	TYR	P14679	1/20	0.39

▸	DRD1	P21728	1/20	0.39

▸	CA4	P22748	1/20	0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compound	similarity	top predicted	shared targets
SCHEMBL28554503	0.93	ESR1 (0.56)	ESR1ESR2NQO2ALDH1A1MAPT
SCHEMBL28093622	0.93	ESR1 (0.56)	ESR1ESR2NQO2ALDH1A1MAPT
SCHEMBL854364	0.93	ESR1 (0.56)	ESR1ESR2NQO2ALDH1A1MAPT
SCHEMBL26827	0.93	ESR1 (0.56)	ESR1ESR2NQO2ALDH1A1MAPT
Pyridine SCHEMBL1237058	0.83	ESR1 (0.46)	ESR1ESR2NQO2ALDH1A1MAPT
Ether SCHEMBL27951660	0.81	NQO2 (0.45)	ESR1ESR2NQO2ALDH1A1MAPT
Coumaric Acid SCHEMBL20261721	0.81	ESR1 (0.62)	ESR1ESR2NQO2MAPTKMT2A
SCHEMBL22691970	0.80	TSHR (0.48)	ESR1ESR2ALDH1A1KMT2ACA1
Gentisic Acid SCHEMBL28367375	0.79	PTGS2 (0.56)	ESR1ESR2NQO2ALDH1A1KMT2A
SCHEMBL670068	0.78	ALDH1A1 (0.46)	ALDH1A1MAPTKMT2AHPGDKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

Patent	Title	Assignee	Published	Priority	Filing	Country	Status
EP-1539730-A4	NOVEL COMPUNDS, PHARMACEUTICAL COMPOSITIONS CONTAINING SAME, AND METHODS OF USE FOR SAME	FASGEN INC (US)	2007-03-28	—	—	EP	disclosed
WO-2007014247-A2	NOVEL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS CONTAINING SAME, AND METHODS OF USE FOR SAME	JOHNS HOPKINS UNIVERSITY (US)	2007-02-01	—	—	WO	disclosed
EP-1534263-A4	NOVEL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS CONTAINING SAME, AND METHODS OF USE FOR SAME	FASGEN LLC (US)	2006-10-11	—	—	EP	disclosed
EP-1539730-A1	NOVEL COMPUNDS, PHARMACEUTICAL COMPOSITIONS CONTAINING SAME, AND METHODS OF USE FOR SAME	Fasgen Inc. (US)	2005-06-15	—	—	EP	disclosed
EP-1534263-A2	NOVEL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS CONTAINING SAME, AND METHODS OF USE FOR SAME	Fasgen, LLC (US)	2005-06-01	—	—	EP	disclosed
WO-2004006835-A2	NOVEL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS CONTAINING SAME, AND METHODS OF USE FOR SAME	FASGEN, LLC. (US)	2004-01-22	—	—	WO	disclosed
WO-2004005277-A1	NOVEL COMPUNDS, PHARMACEUTICAL COMPOSITIONS CONTAINING SAME, AND METHODS OF USE FOR SAME	FASGEN, INC. (US)	2004-01-15	—	—	WO	disclosed